Clinical Trial Update: A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing pegvisomant to Sandostatin LAR Depot for efficacy and safety in acromegaly has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Pegvisomant (pegvisomant)
• SANDOSTATIN LAR DEPOT (OCTREOTIDE ACETATE)

Snippet

Sponsor: Pfizer | Conditions: Acromegaly | Phase 4 | Status: COMPLETED